

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/687,122	10/13/2000	Alessandra Boe	P/717-181(CONT)	6984
1444	7590 06/08/200	4	EXAMINER	
BROWDY AND NEIMARK, P.L.L.C. 624 NINTH STREET, NW SUITE 300			MURPHY, JOSEPH F	
			ART UNIT	PAPER NUMBER
2011-11	GTON, DC 20001-530	3	1646	
			DATE MAILED: 06/08/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Advisory Action	09/687,122	BOE ET AL.			
Advisory Action	Examiner	Art Unit			
	Joseph F Murphy	1646			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address					
THE REPLY FILED 02 April 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.					
PERIOD FOR REPLY [check either a) or b)]					
a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2. The proposed amendment(s) will not be entered because:					
(a) 🛛 they raise new issues that would require further	er consideration and/or search (s	see NOTE below);			
(b) ☐ they raise the issue of new matter (see Note below);					
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or					
(d) they present additional claims without canceling a corresponding number of finally rejected claims.					
NOTE: See Continuation Sheet.					
3. Applicant's reply has overcome the following rejection(s):					
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).					
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.					
5. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.					
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	uld be rejected is provided below	w or appended.			
The status of the claim(s) is (or will be) as follows:	Elyab	ell C. Tammen			
Claim(s) allowed: Claim(s) objected to: <u>30 and 31</u> . Claim(s) rejected: <u>21 and 25-29</u> . Claim(s) withdrawn from consideration: <u>22-24 and 3</u>	F	LIZABETH KEMMERER PRIMARY EXAMINER			
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.					
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)					
10. Other:					
···Li Cuici					

Continuation Sheet (PTOL-303)

Continuation of 2. NOTE: The proposed amendment presents new issues requiring further consideration or search and will not be entered. The proposed amendment to claim 30 changes the autoimmune or inflammatory disease to be treated from the already examined disease septic shock, to the newly presented conditions rheumatoid arthritis, lupus erythematosus or multiple sclerosis. These conditions were not examined previously, and are thus new issues and would require further consideration and a new search. In addition, the proposed amendment to claim 21 adds the new limitation wherein the autoimmune or inflammatory diseases are effectively treated by administration of TNF receptor. Such diseases would require further consideration and a new search, since this limitation was not previously searched.

Continuation of 5. does NOT place the application in condition for allowance because: Applicant's arguments are directed to the new claim limitations, which were not entered..